A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Plexiform neurofibroma
- Focus Therapeutic Use
- 31 Oct 2018 Status changed to recruiting.
- 20 Jun 2018 Planned number of patients changed from 19 to 48.
- 20 Jun 2018 Planned End Date changed from 1 Oct 2019 to 1 May 2022.